Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Meningioma × Cyclophosphamide × Clear all

Phase

Phase 2 2 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 43 Lymphoma, Non-Hodgkin 38 Breast Neoplasms 38 Lymphoma, Large B-Cell, Diffuse 37 Precursor Cell Lymphoblastic Leukemia-Lymphoma 36 Multiple Myeloma 34 Leukemia 31 Leukemia, Lymphocytic, Chronic, B-Cell 30 Melanoma 29 Lymphoma, Follicular 25 Leukemia, Myeloid, Acute 24 Recurrence 23 Lymphoma, B-Cell 23 Lymphoma, Mantle-Cell 22 Ovarian Neoplasms 18 Neoplasm Metastasis 17 Hodgkin Disease 17 Hematologic Neoplasms 17 Pancreatic Neoplasms 16 Myelodysplastic Syndromes 16 Burkitt Lymphoma 16 Carcinoma, Non-Small-Cell Lung 13 Neoplasms 12 Lymphoma, B-Cell, Marginal Zone 12 Colorectal Neoplasms 12 Triple Negative Breast Neoplasms 9 Waldenstrom Macroglobulinemia 8 Uterine Cervical Neoplasms 8 Stomach Neoplasms 8 Lymphoma, Large-Cell, Immunoblastic 8

Interventions

Specimen Handling 2 Magnetic Resonance Spectroscopy 2 pembrolizumab 1 lutetium Lu 177 dotatate 1 gallium Ga 68 dotatate 1 fludarabine 1 Surgical Procedures, Operative 1 Semaxinib 1 Radiosurgery 1 Proton Therapy 1 Nivolumab 1 Lysine 1 Ipilimumab 1 Interleukin-2 1 Imatinib Mesylate 1 Ga(III)-DOTATOC 1 Erlotinib Hydrochloride 1 Cyclophosphamide 1 Crossing Over, Genetic 1 CTLA-4 Antigen 1 Arginine 1 64Cu-SARTATE 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1 177Lu-DOTA-JR11 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06640582 2024-11-05

BAH2472

Essen Biotech

Phase 1/2 Recruiting

Brain Neoplasms, Glioblastoma, Glioma, Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡